Translational studies revealed that DCAF1 blocked the 4G2 antibody with high efficacy and inhibited the ADE process during DENV infection in a cell line model, whereas DCAF4 relieved the disease symptoms by complement cascade inhibition and MAC reduction in a passive transfer myasthenia gravis rat model. This evidence concerns the gene DCAF1 and acute disseminated encephalomyelitis.